

Streamline CMC dossier preparation

→ Actionable intelligence to ensure compliance and boost efficiency

Navigating the regulatory CMC approval process is complex – and costly




50%

of a company's total non-clinical budget is spent on CMC-related activities.¹



\$500K+

is the cost of a delayed launch, per drug, per day.²



18%

of delays following resubmission are due to CMC-related issues.³



Insights for effective pre- and post-approval submission preparation:

Find information and stay up-to-date effortlessly using a centralized platform.



Gain a deep understanding of local practice with information provided by Clarivate's experts.



Compare CMC requirements in English across multiple countries, provided in a CTD Module 3 format for easy navigation.



Plan and manage your submission strategy using the end-to-end pathways, with official and estimated timelines.



Approach each stage of the regulatory CMC approval process with confidence



Risk reduction and increased compliance



Improved processes and efficiency gains



More informed strategy and reduced time to market

7K REGULATORY DOCUMENTS

Pre-approval content:

137

Countries for Small molecules

64

Countries for biologics


Post-approval content:

61

Countries for small molecules & biologics

See Cortellis CMC Intelligence in action

[Contact us here](#)



FOOTNOTES:

- https://www.contractpharma.com/issues/2013-06/view_features/characterizing-the-cost-of-non-clinical-development-activity
- <https://doi.org/10.1007/s43441-024-00667-w>
- <https://jamanetwork.com/journals/jama/fullarticle/1817795>